DETAILED ACTION
1. Claims 1-7, 9-15 are pending in the instant application.
2. New Claim Rejections - 35 USC § 103/102
Claims 1-7, 9-15 are rejected under 103(a)/102(a) as being unpatentable over Snyder et al., US 20210196710 in view of Vetrichelvan et al., PLOS ONE, (09/27/2021), pages 1-16.
Applicants argue that Snyder is silent as to the specific treatment regimen presently claimed. It is Examiner’s position that Snyder discloses the instant claimed compound A to treat prostate cancer. Snyder discloses compound A can be used to treat castrate-resistant prostate cancer. Vetrichelvan et al. disclosed that CYP3A5 inhibition can block androgen receptor signaling, critical for prostate cancer growth. Vetrichelvan showed that bergamottin may suppress prostate cancer growth, especially in African American patients carrying wild type CYP3A5 often presenting aggressive disease. Therefore, treating prostate cancer using compound A with administering of CYP3A5 inhibitor, an efflux transporter is inherently there.
3. Claims 1-7, 9-15 are rejected under 103(a)/102(a) as being unpatentable over Ha et al., Journal of Medicinal Chemistry (2022), 65, 16128-16154 in view of Vetrichelvan et al., PLOS ONE, (09/27/2021), pages 1-16.
Applicants argue that Ha is silent as to the specific treatment regimen presently claimed. It is Examiner’s position that Ha discloses the instant claimed compound A to treat prostate cancer. Ha discloses compound A can be used to treat castrate-resistant prostate cancer. Vetrichelvan et al. disclosed that CYP3A5 inhibition can block androgen receptor signaling, critical for prostate cancer growth. Vetrichelvan showed that bergamottin may suppress prostate cancer growth, especially in African American patients carrying wild type CYP3A5 often presenting aggressive disease. Therefore, treating prostate cancer using compound A with administering of CYP3A5 inhibitor, an efflux transporter is inherently there.
4. Claims 1-7, 9-15 are rejected under 103(a)/102(a) as being unpatentable over Parikh et al., WO 2023200800 in view of Vetrichelvan et al., PLOS ONE, (09/27/2021), pages 1-16.
Applicants argue that Parikh is silent as to the specific treatment regimen presently claimed. It is Examiner’s position that Parikh discloses the instant claimed compound A to treat prostate cancer. Parikh discloses compound A can be used to treat castrate-resistant prostate cancer and reduces the level and/or activity of BRD9. Vetrichelvan et al. disclosed that CYP3A5 inhibition can block androgen receptor signaling, critical for prostate cancer growth. Vetrichelvan showed that bergamottin may suppress prostate cancer growth, especially in African American patients carrying wild type CYP3A5 often presenting aggressive disease. Therefore, treating prostate cancer using compound A with administering of CYP3A5 inhibitor, an efflux transporter is inherently there.
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 10/01/2026
